Glenmark Pharmaceuticals Limited

NSE: GLENMARK

Healthcare Healthcare

₹2,210.2

-0.74%EOD · 19 Oct

Glenmark Pharmaceuticals Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹62,377 Cr

52W Range

₹2538 / ₹1793

Volume

286K

42.3% delivery

1Y Return

+16.8%

P/E Ratio

35.0

P/B Ratio

6.0

ROE

14.1%

Debt / Equity

5.65

Peers in Healthcare

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Glenmark Pharmaceuticals Limited(this stock)	₹2,210.2	₹62,377 Cr	35.0	6.0	14.1%	0.11%
Divi's Laboratories LimitedDIVISLAB	₹9,087	₹2.41 L Cr	83.0	14.5	16.2%	0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM	₹4,558.7	₹1.73 L Cr	72.8	18.4	17.0%	0.83%
Laurus Labs LimitedLAURUSLABS	₹2,069	₹1.12 L Cr	101.8	21.0	17.7%	0.12%
Zydus Lifesciences LimitedZYDUSLIFE	₹1,113.9	₹1.11 L Cr	25.0	4.2	18.3%	0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP	₹7,700	₹1.11 L Cr	54.3	12.0	21.5%	0.25%
Aurobindo Pharma LimitedAUROPHARMA	₹1,621.4	₹93,292 Cr	26.1	2.6	9.9%	0.00%
Mankind Pharma LimitedMANKIND	₹2,253.2	₹93,067 Cr	46.0	5.8	12.4%	0.00%
Max Healthcare Institute LimitedMAXHEALTH	₹830	₹80,785 Cr	56.7	7.7	14.3%	0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice

44/100

Composite score: 40% quality, 30% valuation, 30% momentum

QualityAverage · 43

ValuationAverage · 45

MomentumAverage · 45

High debt load (D/E 5.7)

Technical Indicators

Full analysis · objective math, not advice

Returns

-0.7%

-3.2%

-9.7%

-1.4%

-1.0%

+16.8%

Weinstein Stage

Stage 3 — Topping (distribution)

RSI (14)

26 Oversold

Trend Template

4/7moderate

RS vs Nifty (3M)

+5.0pp

Moving Averages (price vs MA)

20-DMA

₹2318

below

50-DMA

₹2363

below

150-DMA

₹2278

below

200-DMA

₹2218

below

From 52W High

-12.9%

From 52W Low

+23.3%

Support (20D)

₹2181

Resistance (20D)

₹2483

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+4.7% CAGR

Up 8 of last 11 years

Earnings Quality

Accrual-heavy (watch)

OCF / Net Profit = 0.37x · 11/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.